PBLA OTC
Waconia, MN 55387
US
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nant Capital, LLC | P-Purchase | 0 | $0.37 | 2024-11-15 |
| Horvath Susan | A-Award | 25,480 | $0.39 | 2024-10-01 |
| Simpson Jennifer K. | A-Award | 72,800 | $0.39 | 2024-10-01 |
| GOLDMAN SACHS GROUP | S-Sale | 72,874 | $0.71 | 2023-11-08 |
| GOLDMAN SACHS GROUP | 0 | — | 2023-11-07 |